
Aromatase inhibitors in human estrogen-receptor positive breast cancer can cause tumor mutations.
Aromatase inhibitors in human estrogen-receptor positive breast cancer can cause tumor mutations.
Obesity becoming a growing health concern for cancer survivors, specifically breast and colorectal cancers.
Increased genetic knowledge about non-whites could lead to improved knowledge and treatments.
Bacterial differences were seen between tissue from patients with and without breast cancer.
Drug to be evaluated combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
Ribociclib seeking indication for use in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
The FDA has granted breakthrough therapy designation to Novartis's ribociclib (LEE011).
Eli Lily’s clinical trial for abemaciclib will continue as planned.
Updated criteria outlined by ASCO may lead to an increase in the number of breast cancers that test HER2-positive.
Certain mutations influence risk of drug resistance across several cancer types.
Hormones in body fat provide bridge between breast cancer and obesity.
Surgery is performed in a different position than pre-operative breast imaging MRIs.
Perceived memory problems could be linked to stress rather that treatment in breast cancer survivors.
Fluorescence lifetime imaging identifies which breast cancer patients will benefit from specific treatments.
Neratinib and the combination of veliparib plus carboplatin improves breast cancer outcomes.
Support groups and social networking help breast cancer patients manage emotions and stress.
Patients treated for high cholesterol showed improved survival in bowel, breast, lung, and prostate cancers.
Even low-to-moderate drinking can increase cancer risk.
Inferiority ruled for biosimilar of trastuzumab in the treatment of HER2-positive early breast cancer.
Inferiority ruled for biosimilar of trastuzumab in the treatment of HER2-positive early breast cancer.
CBX8 protein may lead to new treatments for breast cancer.
A new study’s findings contradict previous assumptions about IVF and breast cancer risk.
Top news of the day from across the health care landscape.
Mouse models of paclitaxel lower than clinical doses showed an increase of liver metastases.
Nanostructured lipid carriers filled with melatonin may boost chemotherapy efficacy.